Mark Tullij Ciceron Tri Traktata Ob Oratorskom Iskusstve Pdf

Based on the analysis of creative heritage famous Roman orator, philosopher and politician, especially some of his judicial speeches found features applied his rhetorical argument for the purpose of proving and convincing opponents in court proceedings, attention is focused on the fact that determining the theoretical provisions aimed at development of public speaking, justified in the treatises of Cicero, built on a deep knowledge of rethinking and revision thinkers of antiquity, while based on a synthesis of his own practically experience. Antologija mirovoj pravovoj mysli [Anthology of the world legal thought]. Vostochnye civilizacii. Moskva: Mysl, 1999.

Lentano Mario. Tsytseron: mizh rytorykoyu i politykoyu [Cicero: between rhetoric and politics].

Istoriya yevropeyskoyi tsyvilizatsiyi. Borderlands 2 steam activation key free. Rym / pid red. Umberto Eko; per. Kharkiv: Folio, 2014. Kunch Zoryana. Rytoryka [Rhetoric]: pidruchnyk / Zoryana Kunch, Halyna Horodylivska, Iryna Shmilyk. Lviv: Vyd-vo Lviv.

FOOD COMPOSITION AND ADDITIVES GMOtrack: Generator of Cost-Effective GMO Testing Strategies PETRA KRALJ NOVAK Jo ef Stefan Institute, Department of Knowledge Technologies, Jamova 39, 1000 Ljubljana, Slovenia KRISTINA GRUDEN andDANY MORISSET National Institute of Biology, Department of Biotechnology and Systems Biology, Ve na pot 111, 1000 Ljubljana, Slovenia.

Grabar-Passek M. Skyrim missing tesv exe. Mark Tullij Ciceron [Mark Tullius Cicero]. Gody 81–63 do n.

Moskva: Izd-vo ANSSSR, 1962. Antychni literatury. Vstup do tekstiv [Ancient literature. Introduction to text]. Antychna literatura: khrestomatiya. 2-he vyd., dopovn.

Kyyiv: Radyanska shkola, 1968. Antichnaja ritorika kak sistema [Ancient rhetoric as a system]. Antichnaja pojetika. Ritoricheskaja teorija i literaturnaja praktika.

Moskva: Nauka, 1991. Ciceron Mark Tullij. Rechi [Speeches]. Gody 81–63 rr. Moskva: Izd-vo AN SSSR, 1962. Tulliy Tsytseron – vershyna rymskoho krasnomovstva [M.

Tulliy Cicero – top Roman eloquence]. Kyyiv: Lybid, 1990. Ciceron Mark Tullij.

Rechi [Speeches]. Gody 62–43 do n.je. Moskva: Izd-vo AnSSSR, 1962. Promova na zakhyst poeta Arkhiya [Speech in defense of the poet Arhij]. Antychna literatura: khrestomatiya. 2-he vyd., dopovn.

Kyyiv: Radyanska shkola, 1968. Topika [Topeka]. Jestetika: Traktaty. Moskva: Iskusstvo, 1994. Kolotilova N. Arhument do avtorytetu v rytorytsi ta lohitsi [The argument for the authority in rhetoric and logic]. Visnyk Kyyivskoho natsionalnoho universytetu imeni Tarasa Shevchenka.

Seriya: Filosofiya. Politolohiya, 2011. Zahnitko Anatoliy. Slovnyk suchasnoyi linhvistyky: ponyattya i terminy [Dictionary of modern linguistics: concepts and terms]. Donetsk: DonNU, 2012.

Ob oratore [About the speaker].Mark Tullij Ciceron. Tri traktata ob oratorskom iskusstve. Moskva: Nauka, 1972. Bivalentnist rymskoyi pravovoyi diysnosti [Bivalentnist of Roman legal reality]: monohrafiya. Poltava: Poltavskyy literator, 2011.

Rohovych Myroslav. Na varti derzhavy i zakonu [On the watch of State and Law]. Tsitseron Mark Tulliy. Pro derzhavu. Pro pryrodu bohiv.

Kyyiv: Osnovy, 1998. Slovnyk tsyvilnoho prava [Dictionary of civil law] / V. Kharkiv: Faktor, 2012. Rymske pryvatne pravo (kazusy dobrosovisnosti) [Roman private law (integrity incidents)]: navch. Kyyiv: NDI pryvatnoho prava i pidpryyemnytstva NAPrN Ukrayiny, 2013.

This is a clinical trial designed to assess the cardiovascular outcome of long-term treatment with sitagliptin used as part of usual care compared to usual care without sitagliptin in participants with type 2 diabetes mellitus (T2DM) having a history of cardiovascular (CV) disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0%. Primary hypothesis A is that sitagliptin, when used as part of usual care, is non-inferior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint of Major Adverse Cardiovascular Event (MACE) plus.

If hypothesis A is satisfied: hypothesis B is that sitagliptin, when used as part of usual care, is superior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Sitagliptin Drug: Placebo Phase 3. Layout table for study information Study Type: Interventional (Clinical Trial) Actual Enrollment: 14671 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Actual Study Start Date: December 10, 2008 Actual Primary Completion Date: March 30, 2015 Actual Study Completion Date: March 30, 2015. Layout table for additonal information Responsible Party: Merck Sharp & Dohme Corp. ClinicalTrials.gov Identifier: Other Study ID Numbers: 0431-082 2008_523 ( Other Identifier: Merck study number ) 2008-006719-20 ( EudraCT Number ) First Posted: November 13, 2008 Results First Posted: April 15, 2016 Last Update Posted: August 17, 2018 Last Verified: July 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes Plan Description: URL: Additional relevant MeSH terms.